Helmerich & Payne

Helmerich & Payne Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $39.43 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's balance sheet decreases our estimated fair value. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. For example, the firm's debt to EBITDA ratio of 2.6 sits in the bottom 50% globally. With little debt relative to assets, this firm has a "lazy" balance sheet, which can depress returns on invested capital. We believe this is a sign that shares could be expensive.

Conversely, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 66.8%, for example, ranks in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.